Saturday, 18 April 2026 02:38 PM
Advertorial
Pricing From $159/Month, Named Clinician Credentials With NPI Verification, 503A Pharmacy Partners, and What the Latest FDA Compounding Guidance Means for Men Researching Telehealth GLP-1 Access in 2026
LOS ANGELES, CA / ACCESS Newswire / April 18, 2026 / Disclaimers: This material is paid promotional content provided for informational purposes only. It is not independent medical advice, diagnosis, or treatment, and is not a substitute for professional medical evaluation. Prescription decisions are made only by licensed healthcare professionals following individual clinical review. Neither the publisher nor distributor of this material provides medical services. This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or integrity of the information presented.
GLP-1 Program Overview 2026: Telehealth Access, Pricing Structure, and Compounded Semaglutide vs Tirzepatide Explained
The landscape for compounded GLP-1 telehealth programs has shifted significantly in 2026 - both in terms of the regulatory environment and the growing number of platforms now competing for men's attention. If you have been researching your options and trying to figure out what is actually available, what it legitimately costs, and what the program terms and policies really say, this overview is designed to answer those questions directly.
Menergy, operated by Menergy Meds, Inc., is a telehealth platform designed specifically for men seeking clinician-prescribed access to compounded semaglutide and compounded tirzepatide. This overview covers the program structure, pricing, policies, and the regulatory context that men researching this category in April 2026 should understand before enrolling.
Start here: Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are prepared by licensed 503A compounding pharmacies pursuant to individual patient-specific prescriptions. The FDA does not review compounded medications for safety, effectiveness, or quality before they are dispensed. Compounded medications may also differ in formulation, dosage, and inactive ingredients from FDA-approved products. This distinction is fundamental to evaluating any compounded GLP-1 telehealth program in 2026 - and it is addressed fully in the regulatory context section below.
What Is Menergy and How Is the Program Structured
Menergy is a telehealth platform designed specifically for adult men aged 21 and older seeking evaluation for clinician-prescribed GLP-1 therapy. The program involves three separate entities, each with a distinct role - a structure commonly used in telehealth programs involving independent clinicians and pharmacies:
Menergy Meds, Inc. operates the platform, handling intake technology, program administration, and patient coordination. Menergy Meds, Inc. states in its Terms of Service that it is not a medical provider and does not practice medicine.
Lion MD is the independent medical group whose licensed physicians and healthcare providers handle all clinical evaluations and prescribing decisions. These providers are licensed in the patient's state. Every prescription issued through a Menergy consultation is written by an independent licensed clinician - not generated automatically by the platform.
Licensed U.S. 503A compounding pharmacies named on the Menergy website - Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx - dispense medications pursuant to valid patient-specific prescriptions. These pharmacies operate under state pharmacy board oversight.
This three-entity structure is common across telehealth platforms and ensures appropriate separation between the technology platform, clinical decision-making, and medication dispensing.
Who Is Eligible to Use the Menergy Program
Menergy sets a minimum age requirement of 21 for platform access. The program is available to patients in the United States, though availability of specific services may vary by state based on provider licensure and applicable regulations. Patients with questions about availability in their specific state are directed to contact Menergy's support team.
Eligibility for GLP-1 therapy is always determined by the clinician, not the platform. The general eligibility guideline referenced on the Menergy website is a BMI of 27 or higher with at least one weight-related condition, or a BMI of 30 or higher. Whether a specific individual qualifies is assessed during the clinical consultation based on the patient's individual health history and circumstances - not by the intake form alone.
View the current Menergy program details (official Menergy page)
How the Consultation and Prescription Process Works
The intake process at Menergy is fully online. According to the website, the questionnaire takes approximately 10 minutes, after which a licensed clinician reviews the submission and determines whether treatment is appropriate. No prior appointment is required.
Step 1: Complete the online health questionnaire. Patients answer questions about their health history, current conditions, relevant medications, and weight management goals. This information forms the basis of the clinician's evaluation.
Step 2: Clinician review by Lion MD. A licensed physician or healthcare provider from Lion MD, licensed in the patient's state, reviews the intake profile and determines whether GLP-1 therapy is clinically appropriate. If it is, the clinician prescribes the appropriate compound and dosage based on the individual's health profile. Not every person who completes the intake will receive a prescription - that determination rests entirely with the evaluating clinician.
Step 3: Medication dispensed and delivered. The prescription is sent to one of the licensed 503A compounding pharmacy partners named on the Menergy website. According to the platform, medication is shipped in temperature-controlled packaging, and most orders are described as arriving within 3 to 5 business days.
The Lion MD medical team listed on the Menergy website includes Dr. Ana Lisa Carr, MD (NPI: 1689841744) and Dr. Kelly Tenbrink, MD (NPI: 1346482684) as lead clinicians, with supporting practitioners Dr. HirenKimar Italia, MD (NPI: 1487815387) and Dr. David Mansour, DO (NPI: 1689164949). The platform describes a network of more than 50 licensed clinicians available across supported states. NPI numbers can be independently verified through the National Provider Identifier registry at nppes.cms.hhs.gov.
Compounded Semaglutide vs Compounded Tirzepatide: What the Menergy Program Offers
The clinician determines which option is appropriate based on the patient's individual health profile. According to the Menergy website, the platform currently offers two compounded GLP-1 options:
Compounded Semaglutide - $159/month
Semaglutide acts on GLP-1 receptors involved in appetite and metabolic regulation and is a GLP-1 receptor agonist that has been studied in clinical research. According to the website, the monthly plan includes the compounded medication, ongoing clinician oversight, ongoing clinical support, monthly delivery with free shipping, and the ability to cancel before the next billing cycle. Multi-month plans are available with savings described as up to 25%.
Compounded Tirzepatide - $259/month
Tirzepatide acts on both GLP-1 and GIP receptors. The Menergy website lists this as an alternative option within the program. The plan structure is comparable to the semaglutide tier, with clinician oversight, monthly delivery, free shipping, and the same multi-month discount structure. The clinician determines whether tirzepatide or semaglutide is appropriate based on each patient's individual health history and treatment goals.
Both medications are compounded by licensed U.S. 503A compounding pharmacies named on the Menergy website, and both ship in temperature-controlled packaging to maintain medication integrity. Compounded formulations are not FDA-approved finished drug products, are not reviewed by the FDA for safety, effectiveness, or quality before dispensing, and should not be considered equivalent to branded FDA-approved medications such as Wegovy, Ozempic, Mounjaro, or Zepbound.
View the current Menergy program details (official Menergy page)
On Clinical Outcome Data
Some published clinical research on FDA-approved GLP-1 active ingredients has reported substantial average weight-loss outcomes in certain studied populations over periods of 12 to 16 months. Those findings should not be interpreted as guaranteed results for any compounded product, any specific telehealth program, or any individual user. The Menergy website references outcome statistics in its marketing materials - those represent the brand's claims and should be evaluated accordingly. Individual outcomes depend on dosage, adherence, metabolic response, and lifestyle factors. A clinician is the appropriate source for realistic, individualized expectations.
This is ingredient-level research context; compounded semaglutide and compounded tirzepatide as dispensed through the Menergy program have not been independently clinically studied as finished products.
Menergy Pricing, Policies, and What to Know Before Enrolling
The following pricing and policy information is drawn from the Menergy website and Terms of Service as of April 2026. Verify current terms directly at menergymeds.com before enrolling.
Semaglutide plan: $159/month on a monthly billing cycle
Tirzepatide plan: $259/month on a monthly billing cycle
Multi-month savings: According to the website, up to 25% on either plan
Shipping: Free on all plans, per the website
Welcome offer: Code WELCOME100 is referenced on the website for $100 off the first month; promotions are subject to change and may not be available in all cases - verify current availability at menergymeds.com before enrolling
Hidden fees: The platform states no hidden fees
Refund policy - important to understand before purchasing: Menergy's Terms of Service state that all sales are final and there are no refunds or exchanges. Medical consultation fees are explicitly described as non-refundable. This is a firm no-refund policy. Review the full Terms of Service at menergymeds.com/legal/terms before paying.
Cancellation: According to the Terms, monthly plans can be cancelled before the next billing cycle - no long-term contract is required. Multi-month plans are billed upfront at the discounted rate, so cancellation ends future billing rather than triggering a refund on pre-paid amounts. Programs are auto-renewing. Cancellation must occur before the next billing date to avoid the next charge.
Insurance: Menergy is a cash-pay program. According to the Terms of Service, Menergy-affiliated clinicians are not contracted healthcare providers with any health insurance plan, and services are described as cash-pay with insurance generally not billed directly. Patients interested in possible reimbursement should verify directly with their insurer - Menergy does not bill insurance on behalf of patients. Some HSA/FSA plans may reimburse qualifying expenses; check your specific plan rules.
Governing law and disputes: Per the Terms of Service, disputes are governed by Florida law and resolved through binding AAA consumer arbitration. Class action is waived under the Terms.
Ongoing Clinical Support After Enrollment
The Menergy website describes ongoing monitoring as part of the program structure, including individualized dosing adjustments, ongoing clinical support, and direct messaging with the care team. The platform describes this as a medically supervised program rather than a one-time prescription service. Patients are encouraged to confirm specific support details during the consultation process, as program features can evolve over time.
The 2026 Regulatory Context for Compounded GLP-1 Programs
This section covers material that every prospective patient researching compounded GLP-1 telehealth programs should understand in 2026 - not as a deterrent, but as the context needed to make a genuinely informed decision.
What compounded means and what it does not mean. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. The FDA does not verify the safety, effectiveness, or quality of compounded medications before they reach patients. This does not make compounding illegal - 503A compounding pharmacies operate under state pharmacy board oversight and must comply with applicable federal and state compounding regulations - but it is a fundamentally different regulatory pathway than FDA-approved medications.
The shortage resolution and what it means for 503A compounding in 2026. The FDA declared the semaglutide shortage resolved in early 2025, which ended the broad shortage-list exception that had permitted large-scale compounding of essentially-copy semaglutide products. Since then, 503A compounding pharmacies - which operate under patient-specific prescription rules - have continued compounding semaglutide where they can document that the compounded product is not an essentially-copy of the commercially available drug, or where patient-specific clinical need exists (such as allergy to inactive ingredients or dosing requirements not available through approved products). Court challenges brought by pharmacy industry groups also created additional legal complexity throughout 2025 and into 2026.
The April 2026 FDA clarification. On April 1, 2026, the FDA issued additional guidance regarding the compounding of semaglutide, including considerations around formulations combining semaglutide with additional ingredients - such as vitamin B12 - and prescription volume limits for 503A pharmacies. The FDA's guidance addresses whether such combinations may be considered essentially a copy of an FDA-approved product, depending on route of administration and strength, and notes that individual clinical justification should be documented.
Menergy names its pharmacy partners as licensed 503A compounding pharmacies operating under state pharmacy board oversight. Patients are encouraged to ask their clinician directly about the specific compounded formulation that would be prescribed for their case and the pharmacy that would dispense it.
FDA enforcement against misleading marketing. In early 2026, the FDA issued warning letters to telehealth companies for marketing practices that implied compounded GLP-1 products were equivalent to FDA-approved products or obscured the compounding source. These enforcement actions reflect the FDA's active monitoring of this category. This overview has been written to avoid those practices - the compounded status of Menergy's medications is stated clearly and repeatedly.
Side Effects and Contraindications to Discuss With a Clinician
GLP-1 therapy is not appropriate for everyone. The following points are a high-level overview, not a complete list of risks or precautions.
Clinicians evaluate contraindications including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), pancreatitis, and other relevant factors. Common side effects associated with GLP-1 receptor agonists include nausea, decreased appetite, and gastrointestinal discomfort, particularly during early dose titration. More serious potential risks include pancreatitis, gallbladder disease, kidney problems related to dehydration, hypoglycemia in certain patient populations, and allergic reactions.
This is not a replacement for prescribed medical treatment for any health condition. Always consult your physician if you have health concerns, take other medications, or have any questions before starting. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval.
This safety overview is not exhaustive and does not replace the official prescribing information or patient drug education materials. Always review the complete safety information that comes with your prescription and consult your prescriber or pharmacist with any questions.
Who Menergy May Be Right For
The following considerations are based on information presented on the Menergy website and should not be interpreted as recommendations.
Menergy may align well with men who:
Are looking for a clinician-supervised GLP-1 program designed for men. Menergy's platform, intake process, and clinical team are built around adult men aged 21 and older. If you prefer a program that markets specifically to men rather than a general-population telehealth service, this is worth evaluating.
Value transparent pricing without long-term contracts. The monthly pricing structure with no long-term contract requirement and the ability to cancel before the next billing cycle may suit men who want to evaluate the program without committing to extended prepayment - though multi-month plans offer savings for those who prefer that route.
Want verifiable clinical oversight. The fact that Menergy lists specific clinician names and NPI numbers that can be independently verified through the federal NPI registry is a transparency signal worth noting when comparing platforms.
Prefer a cash-pay model with predictable costs. For men who know their insurance won't cover compounded GLP-1 therapy or who prefer to avoid insurance billing complexity, the flat monthly rate with free shipping simplifies the financial picture.
Other options may be preferable for men who:
Need refund flexibility. Menergy's Terms of Service state that all sales are final with no refunds or exchanges. If refund protection is important to you, compare this policy against other platforms before enrolling.
Prefer FDA-approved brand-name medications. Menergy's program involves compounded medications, not FDA-approved finished drug products. Men who want FDA-approved semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro/Zepbound) should discuss those options with their primary care physician or a platform that dispenses brand-name formulations.
Want in-person clinical evaluation. Menergy operates entirely through asynchronous telehealth. Men who prefer face-to-face clinical evaluation may want to explore local providers.
Questions to ask yourself before choosing a compounded GLP-1 telehealth program:
Am I comfortable with the distinction between compounded medications and FDA-approved finished drug products? Do I understand what that means for regulatory oversight of the medication I'll receive?
Have I reviewed the platform's refund policy, auto-renewal terms, and cancellation process - and am I comfortable with those terms before entering payment information?
Have I discussed GLP-1 therapy with my primary care physician, and do I understand the potential side effects, contraindications, and realistic timeline for results?
Am I prepared for this to be a sustained program rather than a short-term intervention - and have I considered the monthly cost over 6 to 12 months or longer?
Your answers help determine whether a compounded GLP-1 telehealth program - and specifically Menergy - fits your individual situation.
View the current Menergy program details (official Menergy page)
Questions Men Ask Before Enrolling in a GLP-1 Telehealth Program
Can I get a GLP-1 prescription online without an in-person visit?
Through telehealth platforms like Menergy, a licensed clinician can evaluate a patient's health profile through an asynchronous online questionnaire and determine whether prescribing is appropriate based on the patient's individual medical profile and applicable state requirements. No in-person visit is required. A valid prescriber-patient relationship is established through the online consultation process.
How long does the Menergy consultation take?
According to the website, the intake questionnaire takes approximately 10 minutes. The clinician review timing is not specified for an exact window - patients should verify current turnaround expectations directly with Menergy at menergymeds.com.
What is the difference between compounded semaglutide and Wegovy or Ozempic?
Wegovy and Ozempic are FDA-approved brand-name medications containing semaglutide as the active ingredient. Compounded semaglutide is prepared by a licensed compounding pharmacy pursuant to an individual prescription. Compounded formulations are not FDA-approved as finished products, are not reviewed by the FDA for safety, effectiveness, or quality before dispensing, and should not be considered equivalent to branded FDA-approved medications. The clinician will explain the distinction and determine which option is appropriate based on the individual patient's circumstances.
Does Menergy accept insurance?
Menergy is a cash-pay program. According to the Terms of Service, clinicians affiliated with the platform are not contracted with health insurance plans, and services are described as cash-pay with insurance generally not billed directly. Patients should confirm with their own insurer whether any reimbursement may be available under their specific plan.
View the current Menergy program details (official Menergy page)
What happens if I want to cancel?
According to the Terms of Service, monthly plans can be cancelled before the next billing date with no long-term contract. Programs are auto-renewing. All sales are described as final with no refunds or exchanges per Menergy's Terms.
Is Menergy available in my state?
The website states that the platform supports patients nationwide, though availability of specific services may vary by state based on provider licensure and applicable regulations. Contact support at menergymeds.com to confirm current availability in your state.
How does Menergy verify prescribing decisions are clinician-driven?
Menergy Meds, Inc. states in its Terms of Service that it does not practice medicine and is not a medical provider. Prescribing decisions are made by independent licensed clinicians associated with Lion MD. The platform provides the technology infrastructure and coordination - the clinical judgment rests with the evaluating provider.
Questions to Ask Your Clinician Before Starting Any GLP-1 Program
Regardless of which platform you choose, these questions can help you have a more informed conversation with the prescribing clinician:
What specific compounded formulation would be prescribed for my case, and which pharmacy would dispense it? Is there a reason a compounded product is being recommended rather than an FDA-approved brand-name medication? What side effects should I watch for during the first few weeks of dose titration, and when should I contact the care team? How will my dosage be adjusted over time, and what does the ongoing monitoring process look like? Based on my individual health profile, what is a realistic timeline and range of outcomes I should expect? Are there any medications I currently take that could interact with GLP-1 therapy?
A clinician who takes the time to answer these questions thoroughly is a positive signal - regardless of which telehealth platform facilitates the consultation.
How to Get Started With Menergy
The consultation begins at the official Menergy website. Prospective patients complete a 10-minute online health questionnaire. A licensed clinician from Lion MD reviews the profile and, if GLP-1 therapy is clinically appropriate, issues a prescription for the compound and dosage determined to fit the patient's individual health profile. The prescription is dispensed by one of the licensed 503A pharmacy partners named on the Menergy website and shipped directly to the patient.
View the current Menergy program details (official Menergy page)
Contact Information
For questions before or during the enrollment process, according to the company's website, Menergy offers customer support:
Company: Menergy Meds, Inc.
Email: [email protected]
Website: menergymeds.com
Final Verdict
The platform presents several attributes that prospective patients may consider: named clinicians whose credentials can be independently verified through the federal NPI registry, named pharmacy partners operating under state pharmacy board oversight, and a defined monthly pricing structure without long-term contracts.
On the other side of the equation, the firm no-refund policy, the inherent limitations of compounded medications that are not FDA-approved finished drug products, and a regulatory environment for compounded GLP-1 programs that continues to evolve in 2026 are all factors that warrant careful evaluation before enrolling.
This overview does not endorse any specific platform but is intended to present verifiable information for independent evaluation.
Important Note: The compounded GLP-1 telehealth category has been under increased regulatory scrutiny in recent years. The FDA has issued warning letters to telehealth companies in this space, resolved the semaglutide shortage (narrowing the legal basis for certain types of compounding), and issued additional clarification in April 2026 regarding 503A compounding of semaglutide combinations. Prospective patients should review the most current information about any platform's compliance, regulatory standing, and the compounded status of the medications being dispensed before enrolling.
The right decision depends on your individual health profile, your comfort level with compounded medications versus FDA-approved formulations, your financial considerations, and - above all - the clinical judgment of a licensed healthcare provider who has evaluated your specific situation.
View the current Menergy program details (official Menergy page)
Disclaimers
FTC Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented in this review. All opinions and descriptions are based on publicly available details and are intended to help readers make informed decisions.
Not Medical Advice: This material is provided for general informational purposes only. It does not constitute medical advice, medical diagnosis, medical treatment, or a recommendation to pursue any specific course of treatment. This advertorial is not a substitute for professional medical evaluation by a qualified, licensed healthcare provider. Reading this material does not create a patient-provider relationship between the reader and any party involved in its production or distribution. Neither the publisher nor the distributor of this material provides medical services of any kind.
Compounded Medication Status: Compounded semaglutide and compounded tirzepatide discussed in this material are not FDA-approved finished drug products. The U.S. Food and Drug Administration has not evaluated compounded versions of these medications for safety, effectiveness, or quality as finished products prior to dispensing. Compounded medications are not manufactured by Novo Nordisk, Eli Lilly, or any other originator manufacturer. They are not the same as, equivalent to, or interchangeable with FDA-approved brand-name medications such as Wegovy, Ozempic, Mounjaro, or Zepbound, and should not be represented or understood as such. Compounded GLP-1 medications may be prepared by licensed 503A compounding pharmacies pursuant to valid patient-specific prescriptions where permitted by applicable federal and state law. The compounding of these medications is subject to evolving FDA enforcement posture and state pharmacy board oversight. Availability of compounded GLP-1 medications may change based on regulatory developments. Patients are encouraged to review current FDA guidance on compounded GLP-1 products before making any enrollment decision.
Regulatory Context: The FDA declared the national semaglutide injection shortage resolved in early 2025, narrowing the legal basis for broad shortage-list compounding of essentially-copy semaglutide products. On April 1, 2026, the FDA issued further clarification reminding 503A pharmacies that compounded semaglutide combined with additional ingredients may still be considered essentially a copy of an FDA-approved product depending on route of administration and strength, and that individual clinical justification must be documented. The FDA has also issued warning letters to telehealth companies for marketing practices implying equivalence between compounded and FDA-approved GLP-1 medications. This material has been written to accurately represent the compounded status of Menergy's medications and does not imply equivalence to any FDA-approved product.
No Guaranteed Outcomes: GLP-1 receptor agonists are prescription medications. Individual responses to any GLP-1 therapy - compounded or brand-name - vary significantly based on dosage, duration of use, individual metabolic factors, adherence to treatment, diet, physical activity, and underlying health conditions. Some published clinical research on FDA-approved GLP-1 active ingredients has reported average weight-loss outcomes in studied populations. Those findings reflect results observed in controlled research settings among studied populations and do not represent expected, typical, or guaranteed outcomes for any individual user, any specific compounded product, or any telehealth program. No outcome, result, or benefit from enrolling in any GLP-1 telehealth program is guaranteed.
Prescription Requirement and Clinical Eligibility: GLP-1 medications - both FDA-approved brand-name formulations and compounded alternatives - are prescription medications. They require evaluation and prescription by a licensed healthcare provider. Enrollment in a telehealth intake process does not guarantee that a prescription will be issued. Prescribing decisions are made solely by the independent licensed clinicians who review each patient's individual health profile. Not every person who completes an intake questionnaire will receive a prescription. GLP-1 therapy is contraindicated for individuals with certain personal or family medical histories, including but not limited to medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2 (MEN2). A complete list of contraindications, warnings, and precautions should be reviewed with the prescribing clinician.
Side Effects: GLP-1 receptor agonists are associated with potential side effects. Commonly reported side effects include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite, particularly during early dose titration. More serious potential risks include pancreatitis, gallbladder disease, kidney problems related to dehydration, hypoglycemia in certain patient populations, and allergic reactions. Questions about the FDA-approved prescribing information for the active ingredients in any GLP-1 compound should be directed to the prescribing clinician and dispensing pharmacy. This overview does not constitute a complete safety disclosure.
Platform Role Separation: Menergy Meds, Inc. states in its Terms of Service that it is not a medical provider, does not practice medicine, and does not prescribe medications. Clinical evaluations and prescribing decisions are made by independent licensed clinicians associated with Lion MD, who are not employees of Menergy Meds, Inc. Medications are dispensed by independent licensed 503A compounding pharmacies - Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx - which are not owned or operated by Menergy Meds, Inc. This role separation is standard in telehealth platform structures and does not alter the patient's obligation to review terms, disclosures, and consent documents on the official Menergy website before enrolling.
Insurance and Payment: Menergy is a cash-pay program. Clinicians affiliated with the Menergy platform are not contracted healthcare providers with any health insurance plan. Services are described as cash-pay with insurance generally not billed directly. Patients who wish to explore potential reimbursement through their health insurance plan should contact their insurer directly. Menergy does not process insurance claims on behalf of patients. Prescription GLP-1 medications - both brand-name and compounded - may or may not be covered under a given health plan depending on the plan design, the diagnosis, and the specific medication. Patients should not assume coverage without confirming with their insurer.
Pricing and Terms Accuracy: All pricing, promotional offers, program terms, and policy information referenced in this material were based on publicly available information on the Menergy website and its legal pages at the time of publication (April 2026). Pricing, promotional codes, program structure, policies, and terms are subject to change without notice. The information in this article may not reflect current terms at the time of reading. Readers should verify all current pricing, terms, and enrollment conditions directly at menergymeds.com before making any enrollment or payment decision.
Consult a Healthcare Professional: Before starting, modifying, or discontinuing any prescription medication or weight management treatment - including any GLP-1 therapy - readers should consult a licensed healthcare professional who can evaluate their individual health history, current medications, relevant contraindications, and treatment goals. This material is not a substitute for that evaluation.
SOURCE: Manergy